MDHearing Volt vs Otofonix Encore

The MDHearing Volt is a budget-priced prescription hearing aid available for $397, earning a B grade with a SoundScore of 3.1/5 in our lab testing. This behind-the-ear, rechargeable device ranks #32 of 36 prescription hearing aids tested, placing it in the top 86% of its category. In our standardized testing, the Volt demonstrates excellent feedback handling at 5.0/5, scoring 0.29 points above the category average. This represents a genuine strength, as the device remained stable under our challenge protocols without audible squealing or whistling. However, speech performance presents significant limitations: speech in quiet scored 1.8/5 (1.57 points below the category average of 3.32), while speech in noise scored 1.0/5 (0.96 points below the 1.96 average). Own-voice comfort measured 2.6/5, a mixed result that falls 0.15 points below the category average. Music streaming is notably limited at 0.0/5, scoring 2.64 points below the category average—users prioritizing phone streaming should consider alternatives. The Volt showed no improvement between Initial and Tuned fits, with both configurations yielding identical scores of 3.1/5. The MDHearing Volt may suit budget-conscious consumers who prioritize basic amplification and excellent feedback stability over speech clarity or streaming features. However, shoppers in this price range should note that alternatives like the RxEars Rxi offer substantially higher performance at similar pricing.

The Otofonix Encore is a behind-the-ear prescription hearing aid priced at $295, placing it in the budget tier of the prescription category. In our lab testing, it earned a C grade with a SoundScore of 2.7/5, ranking 35th out of 36 prescription hearing aids tested. Sound performance presents significant challenges across most metrics. Speech clarity scores are low in both quiet (1.0/5) and noisy environments (1.0/5), falling 2.32 and 0.96 points below category averages respectively. Music streaming capability is essentially absent at 0.0/5, and own-voice comfort is notably limited at 0.1/5 in the tuned configuration—2.65 points below the category average. The one bright spot is feedback handling, which scores an excellent 4.7/5. While this falls just 0.01 points below the category average, it represents strong absolute performance that should minimize whistling issues during daily use. This device runs on disposable batteries. At this price point, shoppers should be aware that the RxEars Rxi offers substantially better sound performance (4.09/5) in the same price range. The Otofonix Encore may suit budget-conscious consumers who prioritize feedback stability over speech clarity and streaming features, but our testing suggests most users would benefit from considering higher-performing alternatives within this price tier.